Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Clinical Trials01:16

Clinical Trials

9.3K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.3K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.9K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.9K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

185
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
185
One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

337
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
337
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

44
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
44

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I-WISh) 2.0.

American journal of hematology·2026
Same author

Engineering single-chain variable fragments to identify pathogenic antibodies in heparin-induced thrombocytopenia.

Blood·2026
Same author

Red blood cell transfusion thresholds in acute leukemia: Current practice and physician perspectives from a national survey.

Transfusion·2026
Same author

Vein-to-vein data: what predicts platelet response?

Blood advances·2026
Same author

Spontaneous Heparin-Induced Thrombocytopenia after Total Hip Arthroplasty.

The New England journal of medicine·2026
Same author

Guideline on the emergency management of critical bleeding in patients with immune thrombocytopenia.

Blood advances·2026
Same journal

Novel variants of the KLF1 gene associated with the In(Lu) phenotype lead to alterations in protein structure.

Transfusion medicine (Oxford, England)·2026
Same journal

Simple image analysis for reliability control of column agglutination test in pretransfusion testing.

Transfusion medicine (Oxford, England)·2026
Same journal

First identification and molecular characterisation of a rare D- - donor in Saudi Arabia.

Transfusion medicine (Oxford, England)·2026
Same journal

Early Haemoglobin response after single-unit red blood cell transfusion predicts repeat transfusion in hospitalised adults: A prospective cohort study and clinical prediction model.

Transfusion medicine (Oxford, England)·2026
Same journal

Identification and protein modelling analysis of a homozygous FUT1*01W.09 variant in a Thai patient with the para-Bombay phenotype.

Transfusion medicine (Oxford, England)·2026
Same journal

Prioritising parameters to minimise blood transfusions for postpartum haemorrhage: A machine learning study using national population data.

Transfusion medicine (Oxford, England)·2026
See all related articles

Related Experiment Video

Updated: Sep 21, 2025

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.4K

Lessons learned from the CONCOR-1 trial.

Jeannie Callum1, Philippe Bégin2,3, Erin Jamula4

  • 1Department of Pathology and Molecular Medicine, Kingston Health Sciences Centre and Queen's University, Kingston, Canada.

Transfusion Medicine (Oxford, England)
|May 28, 2022
PubMed
Summary
This summary is machine-generated.

The CONCOR-1 trial rapidly evaluated convalescent plasma for COVID-19 patients. Lessons learned emphasize preparedness for future pandemics, including pre-drafted trial protocols and tools.

Keywords:
COVID-19blood transfusionconvalescent plasma

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.8K
Author Spotlight: Improving Lesion Contiguity in Pulmonary Vein Isolation via Proactive Esophageal Cooling
05:43

Author Spotlight: Improving Lesion Contiguity in Pulmonary Vein Isolation via Proactive Esophageal Cooling

Published on: April 19, 2024

1.1K

Related Experiment Videos

Last Updated: Sep 21, 2025

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.4K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.8K
Author Spotlight: Improving Lesion Contiguity in Pulmonary Vein Isolation via Proactive Esophageal Cooling
05:43

Author Spotlight: Improving Lesion Contiguity in Pulmonary Vein Isolation via Proactive Esophageal Cooling

Published on: April 19, 2024

1.1K

Area of Science:

  • Infectious Diseases
  • Clinical Trials
  • Hematology

Background:

  • The role of convalescent plasma in treating COVID-19 remained unclear during the evolving pandemic.
  • There was a critical need for robust clinical trial data to guide treatment decisions.

Purpose of the Study:

  • To rapidly design, launch, and complete the CONCOR-1 clinical trial evaluating convalescent plasma for COVID-19.
  • To identify and document key enablers and lessons learned for future pandemic research.

Main Methods:

  • The CONCOR-1 trial was a multi-site, randomized study conducted across three countries involving 940 patients.
  • Utilized a REDCap data platform, virtual meetings, and streamlined regulatory approvals for efficient trial execution.
  • Coordinated efforts across multiple principal investigators, a diverse steering committee, and an international data safety monitoring committee.

Main Results:

  • The CONCOR-1 trial was successfully designed, launched, completed, and submitted for publication within 14 months.
  • Numerous factors facilitated the trial's rapid progression, including dedicated research personnel and streamlined administrative processes.
  • The study highlighted the importance of anticipating the need for specific treatment trials, such as those involving convalescent plasma.

Conclusions:

  • Rapid clinical trial execution is feasible and essential during pandemics.
  • Pre-prepared trial protocols, data collection tools, and adaptable research infrastructure are crucial for future pandemic response.
  • Sharing lessons learned from rapid trials like CONCOR-1 can optimize preparedness for emerging infectious diseases.